Foghorn Therapeutics Inc. (FHTX) stock

FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/300% above fair value

$2.05−0.04 (-1.91%)

Close on Nov 12, 2026Market cap $121.74MP/E 29.3Yield –

Foghorn Therapeutics statistics

75 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Mar 10, 2027 (estimated, after the close)
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 11, 2026

Valuation ratiosIndustry

Market Cap: $124.12M; $289.51M
Enterprise Value: $43.81M; $155.84M
PE Ratio: 29.86; 24.95
PS Ratio: 1.11; 3.63

Enterprise valuationIndustry

EV / Sales: 0.39; 2.62
EV / EBITDA: 11.46; 16.52
EV / EBIT: 18.39; 18.72

Share statisticsIndustry

Shares Outstanding: 59M; 58M
Shares Change (YoY): 9.57%; 10.9%
Shares Change (QoQ): 2.13%; 0.48%
Float: 38M; 49M
Shares Held by Insiders: 36.3%; 12.1%
Shares Held by Institutions: 75.6%; 56.4%

Short sellingIndustry

Short Interest: 2M; –
Short Interest Change: -8.28%; -0.80%
Short % of Float: 5.95%; 9.06%
Short % of Shares Outstanding: 3.79%; 6.30%
Days to Cover: 3.90; 5.15

Stock price statisticsIndustry

52-Week High: $7.61; –
52-Week Low: $1.79; –
20-Day Moving Average: $2.01; –
50-Day Moving Average: $2.90; –
200-Day Moving Average: $4.55; –
Average True Range (14): $0.20; –
Price Change (1 Week): -0.48%; 0.17%
Price Change (1 Month): 13.0%; -1.30%
Price Change (3 Months): -67.8%; -19.3%
Price Change (6 Months): -49.9%; -20.2%
Price Change (YTD): -61.3%; -21.3%
Price Change (1 Year): -52.7%; -20.6%
Price Change (3 Years): -42.3%; -22.2%
Price Change (5 Years): -85.7%; -76.5%
Average Volume (10 Days): 781,912; –
Average Volume (20 Days): 681,050; –
Average Volume (90 Days): 649,730; –
Relative Volume: 1.16; 0.74
Relative Strength Index (14): 42.1; 46.2
Volatility (1 Year): 81.4%; 80.2%
Beta (5 Years): 1.87; 1.07

MarginsIndustry

Operating Margin: 2.13%; -38.5%
Profit Margin: 8.40%; -31.7%
EBITDA Margin: 3.41%; -27.7%
FCF Margin: -74.6%; -8.85%

Returns on capitalIndustry

Return on Assets (ROA): 4.76%; -40.7%
Return on Capital Employed (ROCE): 1.55%; -38.1%

Financial positionIndustry

Current Ratio: 4.24; 3.30
Quick Ratio: 2.15; 2.40

GrowthIndustry

Revenue Growth (YoY): 357.3%; 7.26%
Revenue Growth (3Y CAGR): 17.1%; 2.25%
Revenue Growth (5Y CAGR): 135.1%; 6.41%

EfficiencyIndustry

Asset Turnover: 0.57; 0.40
Revenue Per Employee: $1.06M; $429.38K
Profits Per Employee: $88.87K; -$683.67K
Employee Count: 106; 75
WACC: 14.2%; 10.1%

Income statement (TTM)Industry

Revenue: $112.13M; $66.69M
Operating Income: $2.38M; -$20.99M
Net Income: $9.42M; -$21.61M
EBITDA: $3.82M; -$16.85M
EPS (Diluted): $0.07; -$0.75

Balance sheetIndustry

Cash & Short-Term Investments: $80.30M; $66.80M
Net Cash (Debt): $80.30M; $16.56M
Net Cash Per Share: $1.35; $0.71
Equity (Book Value): -$14.08M; $52.23M
Book Value Per Share: -$0.24; $1.50
Tangible Book Value: -$14.08M; $26.10M
Working Capital: $121.00M; $78.41M

Cash flow (TTM)Industry

Operating Cash Flow: -$83.62M; -$12.27M
Capital Expenditures: -$57.00K; -$944.00K
Free Cash Flow: -$83.68M; -$18.20M
FCF Per Share: -$1.41; -$0.42

Dividends and yieldsIndustry

Earnings Yield: 7.59%; -20.1%
FCF Yield: -67.4%; -9.18%

Scores and fair valueIndustry

Altman Z-Score: -2.66; 0.31
Piotroski F-Score: 2; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

Period	FHTX	S&P 500	Difference	FHTX per year	S&P 500 per year
1 month	+5.1%	-2.7%	+7.8 pts
3 months	-69.1%	-1.7%	−67.4 pts
Year to date	-62.0%	+11.9%	−73.9 pts
1 year	-54.7%	+12.0%	−66.7 pts
3 years	-36.5%	+78.2%	−114.7 pts	-14.1%	+21.2%
5 years	-86.0%	+73.2%	−159.2 pts	-32.5%	+11.6%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

2M FHTX shares were sold short on Oct 30, 2026, down 8.3% from the previous report, or 5.95% of the shares available to trade. At recent volumes it would take 3.9 days to buy them back. Over the last 20 sessions, 33.3% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	2,251,943	-8.3%	577,107	3.9
Oct 15, 2026	2,455,127	+14.1%	2,096,958	1.2
Sep 30, 2026	2,152,592	+8.0%	504,877	4.3
Sep 15, 2026	1,992,972	+1.2%	383,029	5.2
Aug 31, 2026	1,969,434	+10.2%	424,574	4.6
Aug 14, 2026	1,786,939	+11.4%	250,658	7.1
Jul 31, 2026	1,603,855	+4.4%	209,694	7.7
Jul 15, 2026	1,535,862	-3.7%	497,170	3.1
Jun 30, 2026	1,595,520	+14.4%	285,580	5.6
Jun 15, 2026	1,394,668	-5.3%	162,928	8.6
May 29, 2026	1,473,020	+9.8%	179,008	8.2
May 15, 2026	1,341,349	-1.2%	140,046	9.6

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Foghorn Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is FHTX.

Compare: FHTX vs TNGX · FHTX vs FULC · FHTX vs RCUS · FHTX vs PGEN · FHTX vs BCYC

Revenue growth357.3% · median -58.3%

Operating margin2.1% · median -189.4%

Net margin8.4% · median -169.8%

Company	Revenue	Growth
PGEN	$156.94M	–
FHTX	$112.13M	+357.3%
RCUS	$100.00M	-58.3%
BCYC	$83.53M	+194.7%
TNGX	$0	-100.0%
FULC	–	–

Company

Next earnings (est.): Mar 10, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 106
Held by institutions: 75.6%
Auditor: Deloitte& Touche LLP
SEC CIK: 1822462

Advertisement
300 × 250

See a number that looks wrong?